Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Danicopan Add-on Therapy to C5 Inhibitors in PNH With Extravascular Hemolysis
2019-003829-18Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Danicopan add-on to C5 inhibitor with Placebo add-on to C5 inhibitor (2 arms). Primary endpoint: Change from baseline in hemoglobin. Started Jan 2020; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2019-003829-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003829-18.